RT Book, Section A1 Weinstock, Matthew A1 Avigan, David A2 Kaushansky, Kenneth A2 Prchal, Josef T. A2 Burns, Linda J. A2 Lichtman, Marshall A. A2 Levi, Marcel A2 Linch, David C. SR Print(0) ID 1180478006 T1 Immune Cell Therapy: Dendritic Cell and Natural Killer Cell Therapy T2 Williams Hematology, 10e YR 2021 FD 2021 PB McGraw-Hill Education PP New York, NY SN 9781260464122 LK hemonc.mhmedical.com/content.aspx?aid=1180478006 RD 2024/03/28 AB SUMMARYSince their discovery in the early 1970s, dendritic cells (DCs) and natural killer (NK) cells have tantalized immunologists and cancer researchers with their immunotherapeutic potential to control certain neoplasms, including the hematologic malignancies. The current generation of DC-based vaccinations against acute myelogenous leukemia and myeloma has demonstrated promise in this regard. Early-phase clinical trials of allogeneic NK cells, both in haploidentical allogeneic hematopoietic stem cell transplant and as a stand-alone treatment, have also found encouraging results. Future directions of research will include efforts to augment the immune response to DC-based vaccination and allogeneic NK cells. These approaches are in clinical trials. Further laboratory research is exploring the nature, function, and regulation of DCs and NK cells in the tumor microenvironment. These efforts should result in more efficient and effective DC- and NK cell–based immune effector cell therapies with enhanced clinical activity against the hematologic malignancies.